Treatment of Cartilage Defects With Peripheral Blood Stem Cells
NCT ID: NCT04953572
Last Updated: 2021-07-08
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE1
252 participants
INTERVENTIONAL
2021-08-01
2023-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Tissue Engineered Cartilage to Repairing Articular Cartilage Defects
NCT07094100
Treatment of Knee Osteoarthritis With Autologous Adipose-derived Mesenchymal Stem Cells
NCT04212728
The Comparison of Efficacy and Safety of the Mesenchymal Stem Cells From Adipose and Hyaluronic Acid
NCT03357575
Clinical Study of Umbilical Cord Mesenchymal Stem Cells (UC-MSC) for Treatment of Knee Osteoarthritis
NCT03166865
Effectiveness of Autologous Adipose-derived Stem Cells in the Treatment of Knee Cartilage Injury
NCT03955497
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
2. Exploring the characteristics of cartilage regeneration in autologous peripheral blood mesenchymal stem cell transplantation
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
test group
Patients in the test group received autologous peripheral blood mesenchymal stem cell therapy
autologous peripheral blood mesenchymal stem cell
Transplantation of autologous peripheral blood mesenchymal stem cell
control group 1
Patients in the control group 1 received microfracture surgical treatment
Microfracture
Microfracture
control group 2
Patients in the control group 2 received microfracture combined with surgical treatment of collagen membrane
Microfracture + collagen membrane
Microfracture plus collagen membrane transplantation
control group 3
Patients in the control group 3 received autologous osteochondral transplantation
Autologous osteochondral transplantation
Autologous osteochondral transplantation
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
autologous peripheral blood mesenchymal stem cell
Transplantation of autologous peripheral blood mesenchymal stem cell
Microfracture
Microfracture
Microfracture + collagen membrane
Microfracture plus collagen membrane transplantation
Autologous osteochondral transplantation
Autologous osteochondral transplantation
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Symptoms, signs and imaging changes are consistent with knee joint limitations IV cartilage defect or patella chondromalacia, patellofemoral joint cartilage injury, mild to moderate knee osteoarthritis.
3. Other treatments are ineffective.
4. No treatment for other knee cartilage defects during the specified period of the test.
5. The subject must be able to communicate well with the researcher and comply with the research requirements, and must give written, signed and dated informed consent before conducting any research-related activities. All relevant legal representatives will also sign a written research agreement in accordance with local laws and regulations.
Exclusion Criteria
2. Grade Ⅲ and Ⅳ knee joint OA.
3. The patient's symptoms and signs are not closely related to the cartilage defect area.
4. Suffering from concomitant inflammatory diseases (such as rheumatoid arthritis), osteochondrotis dissecans, sepsis, osteonecrosis, and various tumor diseases in the past; in the past three months, there was in the joint cavity of the affected knee History of injection.
5. Suffer from the underlying medical conditions (including but not limited to metabolism, hematology, kidney, liver, lung, nerve , Endocrine, heart, infection, or gastrointestinal tract); currently suffering from a serious progressive or uncontrolled disease that is not suitable for the test or puts it at high risk, including the researchers belief that it will prevent the subject from following the protocol or completing the study according to the protocol Any medical or psychiatric condition of
6. Being infected with human immunodeficiency virus (HIV), infectious hepatitis B or hepatitis C or corresponding medical history.
7. Suffer from a progressive infection or malignant disease, and be able to produce chest X-ray, computed tomography (CT scan) or MRI evidence within 12 weeks before screening, and be evaluated and confirmed by a qualified physician.
8. Active systemic infections (except colds) or any other infections that will recur regularly in the previous two weeks.
9. There is a history of chronic or recurrent infectious diseases, or evidence of tuberculosis infection that was judged to be positive at the time of screening. Subjects who have obtained positive or uncertain results can participate in the study if they undergo a comprehensive tuberculosis examination (according to local practice/guidelines) within 12 weeks before baseline and finally prove that there is no evidence of active tuberculosis. If the presence of latent tuberculosis is confirmed, treatment must be initiated and maintained in accordance with local or national guidelines before the baseline.
10. History of lymphoproliferative disease, or any known malignant tumor, or history of malignant tumor of any organ system in the past 5 years (Bowen's disease, basal cell carcinoma, or actinic keratosis after treatment and no evidence of recurrence in the past 12 weeks Except for diseases; except for excised cervical carcinoma in situ or non-invasive malignant colon polyps).
11. Suffer from medical problems at the same time, including but not limited to the following:
12. Uncontrolled hypertension (systolic blood pressure ≥160mmHg and/or diastolic blood pressure ≥95mmHg), congestive heart failure (New York Heart Association status classification III or IV).
13. Subjects whose serum creatinine level exceeds 2.0 mg/dl (176.8 μmol/L).
14. Total white blood cell (WBC) count at screening \<2500/μL, or platelet \<100000/μL or neutrophil \<1500/μL or hemoglobin \<8.5 g/dL.
15. For pregnant or lactating women, pregnancy is defined as the state of a woman after conception until the termination of pregnancy, which is confirmed by the positive result of the hCG laboratory test.
16. Women with childbearing potential are defined as all women who are physiologically able to become pregnant, unless they use effective contraceptive methods during the entire study treatment administration period.
17. In the six months before the baseline, there is a history of alcohol or drug abuse or evidence of ongoing abuse.
18. A history of allergies to the components of the therapeutic drugs used.
19. The returning visitors cannot be tracked in time.
18 Years
60 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Inner Mongolia People's Hospital
OTHER
Hebei Medical University Third Hospital
OTHER
Tianjin Hospital
OTHER
Peking University Third Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Yu Jiakuo
Chief physician
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Jia-kuo Yu, Prof.
Role: STUDY_CHAIR
Peking University Third Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Institute of Sports Medicine, Peking University Third Hospital
Beijing, Beijing Municipality, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
PekingUTH001
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.